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Abstract
Background—Like many infectious agents, yellow fever (YF) virus only causes disease in a 
proportion of individuals it infects and severe illness only represents the tip of the iceberg relative 
to the total number of infections, the more critical factor for virus transmission.
Methods—We compiled data on asymptomatic infections, mild disease, severe disease (fever 
with jaundice or hemorrhagic symptoms) and fatalities from 11 studies in Africa and South 
America between 1969 and 2011. We used a Bayesian model to estimate the probability of each 
infection outcome.
Results—For YF virus infections, the probability of being asymptomatic was 0.55 (95% credible 
interval [CI] 0.37– 0.74), mild disease 0.33 (95% CI 0.13–0.52) and severe disease 0.12 (95% CI 
0.05–0.26). The probability of death for people experiencing severe disease was 0.47 (95% CI 
0.31–0.62).
Conclusions—In outbreak situations where only severe cases may initially be detected, we 
estimated that there may be between one and seventy infections that are either asymptomatic or 
cause mild disease for every severe case identified. As it is generally only the most severe cases 
that are recognized and reported, these estimates will help improve the understanding of the 
burden of disease and the estimation of the potential risk of spread during YF outbreaks.
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Yellow fever (YF) virus causes intermittent epidemics of severe illness and death affecting 
thousands of people.1 Human and non-human primates are the main amplifying hosts of YF 
virus with both species experiencing sufficient viremia to infect naïve mosquitoes, 
predominantly of Aedes and Haemagogus species.1 Therefore, knowing the number of 
infected individuals is important for estimating the scope of an outbreak, the potential for 
amplification and spread of the virus and the potential burden of disease cases on the 
healthcare system. However, like many infectious agents, YF virus only results in disease in 
some of the individuals whom it infects. Thus, while deaths and severe illness with 
characteristic signs like jaundice and hemorrhage are good indicators of a case or an 
outbreak, they actually only represent the tip of the iceberg relative to the total number of 
infections, the more critical factor for the dynamics of transmission and spread.
To determine the relationship between severe disease and the incidence of YF virus 
infection, it is important to simultaneously measure the incidence of infection, mild disease, 
severe disease and death. However, identifying asymptomatic or mild infections require 
active surveillance, cohort studies or seroprevalence studies. This typically does not happen 
during YF outbreaks that generally occur in areas with limited health resources that are often 
difficult to access. In outbreaks, severe cases of YF are the primary indicator of risk as they 
can be fairly easily identified in healthcare facilities and communities.
Monath et al. used data from a 1978–79 outbreak in The Gambia to estimate that there were 
12 inapparent YF virus infections for every severe case with fever and jaundice.2 Additional 
data from the 1986 and 1987 outbreaks in Nigeria led to a revision of this estimate to 
approximately seven inapparent infections per severe case.3–5 In Brazil, Vasconcelos et al. 
estimated a similar ratio of severe disease to mild or asymptomatic infections.6 Thus, across 
several outbreaks in different countries and continents, approximately one out of every eight 
(13%) YF virus infections resulted in severe disease. These estimates, however, are all point 
estimates and thus do not capture the uncertainty associated with the very limited data used, 
and do not fully utilize other data sources or define the range of disease experienced, such as 
fever without jaundice or other symptoms associated with severe YF.
There is also uncertainty about the case fatality rate (CFR) for YF, with estimates varying 
from approximately 1–15% in Nigerian villages7 to over 80% among hospitalized cases in 
Senegal.8 Part of this wide range is likely attributable to small sample sizes and differences 
in case definitions and how cases are identified.
To better define the probabilities of asymptomatic infection, mild disease, severe disease 
and death associated with YF virus infection, we identified 11 studies with detailed 
information on the prevalence of a variety of these outcomes.2–4,6–12 These studies involve a 
variety of methods and study populations, including varying case definitions, survey 
designs, diagnostic methods, locations, underlying rates of vaccination and previous 
exposure. We combined the data from these studies in a Bayesian model to estimate the 
number of YF virus infections occurring in the populations where these outbreaks occurred, 
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and the probability of asymptomatic infection, mild disease, severe disease and death for 
persons infected by YF virus.
Materials and methods
Case definitions
For the purpose of surveillance in the context of an outbreak, a probable YF case has been 
defined as an acute febrile illness with hemorrhagic symptoms or jaundice.13 We utilized 
this definition to develop three disease categories of persons infected with YF virus: 
asymptomatic (A): no symptoms; mild (M): some symptoms but no hemorrhagic symptoms 
or jaundice and severe (S): fever with hemorrhagic symptoms or jaundice or death.
We opted not to include more specific information on severe symptoms or manifestations, 
other than jaundice and hemorrhage, because most studies did not include that level of 
detail.
Data
Using expert knowledge, literature searches and chains of references, we identified 11 
studies with detailed information on the prevalence of different disease outcomes in 
populations where confirmed YF outbreaks had recently occurred or were ongoing. The 
nature of the data was highly varied, with some data being directly relatable to infection or 
disease on the population level (Table 1). We have presented this in terms of the 
classifications above: A, M and S, as well as F (fatal cases), YF virus-related deaths and N, 
any person in the population. For each pair of columns in Table 1, the left column represents 
the number of people in a given category sampled from the population in the right column. 
For example, in Okwoga-Okpudo, there were 21 mild and severe cases among a sample of 
131 people from the general population. Among the whole population, of 201 people, there 
were 1–5 deaths attributable to YF virus. Further details of the data selected from each study 
are presented in the Supplementary data.
Other data measured infection or disease among a group of people that was not directly 
related to a general population (Table 2); for example, the number of fatalities among severe 
cases of unknown or unreported provenance. For this analysis, we considered all reported 
YF deaths as resulting from severe illness, even if neither jaundice nor hemorrhagic fever 
was reported. Many YF cases die due to renal failure or cardiac arrest,14 and do not develop 
hemorrhagic symptoms or jaundice before dying.7 It is likely that most fatal cases would 
have developed jaundice or hemorrhagic symptoms if they had lived longer.
Because all cases were reported in the context of outbreaks, we included all individuals 
meeting the severe case definition with or without evidence of laboratory confirmation. For 
asymptomatic infections, mild infections and deaths without severe manifestations, we 
included only persons with YF virus infection demonstrated by: 1. detection of YF virus 
antibodies using an IgM ELISA or immunofluorescent antibody test (IFA), complement 
fixation or plaque reduction neutralization test; 2. detection of YF virus by culture; 3. 
detection of viral antigens using immunohistochemistry; or 4. detection of viral genome by 
RT-PCR. Antibody-based testing was considered confirmed only if previous vaccination 
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coverage in the studied population was non-existent or low, or if it was clearly stated that the 
individuals being tested had not been vaccinated. Further details about the data selected for 
analysis are available in the Supplementary data. All data used in this study were collected 
from previously published material and thus did not require ethical review.
Model description
For each population that was sampled, we assumed that there was a community-wide 
probability of infection (pI) during the outbreak. We assumed that the probability of 
infection for each outbreak population (i) was independent, as transmission dynamics may 
vary due to local environmental, human, mosquito or virus characteristics:
Where Ii is the number of people infected and Ni is the total population size.
Among those infected, we assumed that a proportion experienced asymptomatic infection 
(pA|I), mild disease (pM|I) or severe disease (pS|I), with pA|I+pM|I+pS|I= 1. These proportions 
may vary between studies (s), depending on how cases were defined and sought and 
depending on the characteristics of the human, mosquito and virus populations associated 
with the outbreak. Therefore, we assume that there may be some study-to-study variation in 
observed disease proportions, which we account for using a random effect:
and
The three probabilities were then standardized by dividing by their sum ensuring that they 
sum to one, i.e. that every infected individual has one of these outcomes.
As described above, we assumed that all fatalities came from among the severe cases. We 
assumed that this probability of fatality (pF|S) may also be influenced by study methods or 
differences in local transmission characteristics:
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We designed a hierarchical Bayesian model to specify each of the observed components in 
Table 1 as a binomial sample of the relevant population, related to the probabilities of each 
disease classification across studies. In studies with an observed number of asymptomatic 
infections (A), mild and severe cases (M+S), severe cases (S) or fatal cases (F) in a random 
sample population (N) the parameters are related to the probabilities of infection and disease 
outcome as follows:
and
In studies with an observed number of asymptomatic infections (A) in a sample of 
individuals with no history of disease (NA):
In studies reporting asymptomatic infections and mild cases (A+M) among people with a 
history of no severe disease (N!S):
For the data that was not directly linked to a population sample (Table 2), we used the 
following distributions:
where NAM is the number of people with asymptomatic or mild infections,
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We fitted the model using Markov Chain Monte Carlo methods in OpenBUGS Version 
3.2.115 using the R2OpenBUGS package16 in R Version 2.15.13.17 We used vague beta 
priors (Beta[1, 1]) for each probability and vague gamma priors for each local precision 
parameter (1/σ2∼Gamma[1, 1]). Three chains were initialized with different initial 
probability values and checked for convergence and autocorrelation. We discarded the initial 
20 000 samples, and used over relaxation and thinning at every 300 samples to obtain 1000 
uncorrelated samples of each parameter. Posterior distributions for unobserved quantities 
were estimated conditionally on other location-specific observed components and on the 
global parameter posterior distributions.
Results
For individual studies, the estimated YF virus infection outcome probabilities varied, falling 
between the estimated overall mean and the observed proportion in studies where it was 
available (Figure 1). The estimated variances for the random effects on the logit-transformed 
probabilities were 0.9 (95% credible interval [CI] 0.3–9.3) for pA|I, 1.2 (95% CI 0.3–13.9) 
for pM|I, 0.55 (95% CI 0.2–3.7) for pS|I and 0.6 (95% CI 0.3–2.5) for pF|S. This variability 
may arise from natural variation, differences in study methods or a combination of both. We 
thus estimated the credible intervals for the average probabilities across studies and for the 
expected probability for an unknown area with unknown study methods (Table 3). The 
overall estimate for the probability of a YF virus infection being asymptomatic was 0.55 
(95% CI 0.37–0.74) (Figure 2). The probability of infection resulting in mild disease was 
0.33 (95% CI 0.13–0.52) and severe disease was 0.12 (95% CI 0.05–0.26). The probability 
of severe disease resulting in death or CFR was 0.47 (95% CI 0.31–0.62). Overall, 5% (95% 
CI 2–12%) of infections and 13% (95% CI 5–28%) of those with mild or severe disease, i.e. 
any sign of disease, resulted in death.
Based on these results, 9 (95% CI 1–70) mild and asymptomatic infections would be 
expected for every severe case during a new outbreak; with the credible interval including 
the variability associated with the random effects. For each death due to YF virus, there may 
be 21 other infections (95% CI 3–239), including 12 asymptomatic infections (95% CI 1–
145), 8 mild cases (95% CI 0–100) and 1 non-fatal, severe case (95% CI 0–9).
Discussion
For most pathogens, observed disease only represents a small fraction of all infections. 
Furthermore, estimation of the true infection rate generally relies on limited data of varied 
quality with potential cofactors that are unknown or unobserved. Our Bayesian approach to 
YF virus infections and disease allows for controlling for different study designs and study 
populations, while exploiting all available data, and accounting for uncertainty.
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Using data from 11 YF investigations, we described the proportion of YF virus infections in 
humans that are likely to be asymptomatic or result in mild or severe disease. Approximately 
55% of infections were asymptomatic, 33% resulted in mild disease and 12% resulted in 
severe illness characterized by fever with jaundice or hemorrhagic symptoms. These 
estimates are generally in-line with previous estimates of severe versus inapparent (i.e. 
asymptomatic or mild) infections.2–6
Our estimated CFR of 47% among severe cases is similar to previous estimates of 40–
50%.3,9,10,14,18 However, CFR did vary substantially from other point estimates, likely due 
to sample size limitations, different methods and case definitions. Observations from 
Nigeria, The Gambia and Uganda, for example, had only a handful of known deaths in each 
community, so the observations of 1–25% CFR are based on very few severe cases.2,7,12 In 
the 1978 Nigeria outbreak, the overall estimated CFR was 21%, but included substantial 
underreporting in the largest study population.4 In the two more thoroughly assessed 
communities, the observed CFR was much higher, 50% and 75%, but again the sample size 
was very limited in those populations.4 In other studies from Brazil6 and Senegal,8,11 CFRs 
of 16–28% were reported, but the denominators included at least some people with mild 
rather than severe disease as we have defined it here. When we included mild disease in our 
case definition, the CFR decreased to 12%. Studies may also overestimate the CFR if they 
capture mostly hospitalized cases, as deaths may be more likely to be captured than non-
fatal severe cases.14 The CFR may also appear higher when there is overrepresentation of 
the most severe cases, such as in routine surveillance systems, where only the most severe 
diseases are likely to be captured. For example, among 4066 cases reported to the Pan 
American Health Organization between 1985 and 2012, 58% died, almost the upper limit of 
the credible interval estimated here.17
Despite using carefully screened data from 11 different studies, all of our estimates contain a 
high amount of uncertainty as reflected in the large credible intervals. These intervals reflect 
both uncertainty due to data limitations, as discussed above, and natural variability that may 
be intrinsic or related to heterogeneities between the outbreaks. Uncertainty in the data 
comes from the paucity of published YF outbreak studies, the limited amount of data from 
small samples in those studies, varying study designs and difficulty in measuring outcomes. 
For example, the number of deaths due to YF virus may be overestimated if it includes all 
deaths with fever and jaundice (including hepatitis fatalities, for example) or underestimated 
if only laboratory-confirmed cases are accepted.9 Factors contributing to spatiotemporal 
heterogeneity in infection rates and potentially disease rates include: the local 
environment,19,20 characteristics of the human, vector and virus populations,21 pre-existing 
YF virus immunity due to previous exposure or vaccination, interventions in response to 
outbreaks, and the prevalence of other health conditions that may influence the severity of 
disease (such as malnutrition or HIV infection). In fact, most of the investigations reviewed 
here were accompanied or immediately followed by vaccination campaigns.2–4,6–8,10–12
There are several limitations to the approach we have used to estimate the probability of 
each infection outcome. In the model, intra-study variability was captured in the random 
effects as there was not enough information to assess differences related to specific sources 
of heterogeneity. The credible intervals for individual studies and the expected credible 
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intervals for a new study were particularly large, implying that estimation from individual 
studies was highly dependent on the characteristics of the study and the study population. 
The random effects do not allow us to distinguish between these factors, but do allow the 
estimation of average global rates given the presence of local differences across the diverse 
group of outbreaks included in the analysis.
Conclusions
For many disease outbreaks, it is usually the severe cases that are first detected, as they are 
more recognizable.22–25 For YF virus, the severe form of the disease is more recognizable, 
but may represent an additional three to twenty asymptomatic or mild infections. For any 
observed case, there is likely a larger problem with appreciable potential for further 
infections, a fact that has long been implicitly recognized. The International Health 
Regulations accordingly state that a single observed YF case is sufficient to trigger an 
assessment of global risk.26 As for other infectious diseases, understanding how the 
incidence of YF virus infection relates to the occurrence of severe cases is critical to 
decision-making and the implementation of appropriate responses and interventions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Estimates for yellow fever virus infection outcomes for individual studies and the overall 
averages. For each individual study and the overall model, the mean estimates (points) and 
95% credible intervals (lines) are shown for the probabilities of being asymptomatic (pA|I), 
having mild symptoms (pM|I) or severe symptoms (pS|I) given yellow fever virus infection. 
The case fertility ratio (CFR) is the probability of a severe case resulting in a fatality. For the 
studies with relevant observed data (Table 1), the crude rates from those observations are 
indicated by an x.
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Estimates for yellow fever (YF) virus infection outcomes. The left panel indicates the 
expected percentage of YF virus infected people in each disease category with 95% credible 
intervals in parentheses. The right panel indicates the probability of fatal outcomes among 
severe cases with 95% credible intervals in parentheses.
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Table 3
Probability of yellow fever (YF) virus infection outcomes
Mean Overall 95% CIa New study 95% CIb
Among infected
 Asymptomatic pA|I 0.55 0.37–0.74 0.1–0.87
 Mild pM|I 0.33 0.13–0.52 0.02–0.75
 Severe pS|I 0.12 0.05–0.26 0.01–0.45
Among severe
 Fatal pF|S 0.47 0.31–0.62 0.10–0.84
a
95% credible interval for overall mean.
b
95% credible interval for a new study in an unknown location.
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